Plain English Summary
Background and study aims
Steroids can be used in the treatment of patients with knee osteoarthritis (arthritis of the knee), but the best agent is still unknown. This study aimed to compare the effect of two drugs (triamcinolone hexacetonide and methylprednisolone acetonide) on the condition.
Who can participate?
Men and women who are at least 40 years old, with painful knee osteoarthritis took part in this study.
What does the study involve?
Participants were randomly allocated to receive a single knee injection of either triamcinolone hexacetonide or methylprednsilone acetonide. After 24 weeks participants attended a follow-up visit to assess the effectiveness of the treatment with questionnaires.
What are the possible benefits and risks of participating?
Possible benefits were pain relief and physical function improvement. Risks were related to the injection and included pain, swelling, bleeding and infection in the knee.
Where is the study run from?
The study was run from Hospital Heliópolis, São Paulo, Brazil
When is the study starting and how long is it expected to run for?
The study started in December 2010 and ended in May 2013
Who is funding the study?
The investigators funded the study
Who is the main contact?
Dr Andrea Lomonte
A randomized, double-blind study to evaluate the efficacy of intra-articular injection of methylprednisolone versus triamcinolone hexacetonide in patients with knee osteoarthritis
Intra-articular injections of methylprednisolone acetate and triamcinolone hexacetonide have similar efficacy at reducing knee pain and improving physical function both in the short as in the long-term in patients with symptomatic knee osteoarthritis.
Research Ethics Committee of the Hospital Heliopolis [Comitê de Ética em Pesquisa do Hospital Heliópolis], 14/10/2008
24 weeks prospective randomized two arms double-blinded study
Primary study design
Secondary study design
Randomised controlled trial
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
1. Intra-articular triamcinolone hexacetonide 40mg single dose
2. Intra-articular methylprednisolone acetate 40mg single dose
Total duration of the study: 24 weeks
Intervention was one day (single injection)
Follow-up: 24 weeks
Methylprednisolone, triamcinolone hexacetonide
Primary outcome measure
Mean change from baseline in patients assessment of pain in the targeted knee by VAS at week 4
Secondary outcome measures
1. Mean changes from baseline in patients assessment of pain by VAS at 12 and 24 weeks
2. Mean changes from baseline in patients and physicians global assessment of disease activity by VAS
3. Improvement in patients global assessment of disease by Likert scale
4. Mean changes from baseline in total Western Ontario and McMaster Universities (WOMAC) questionnaire and its subscores of pain, stiffness and physical function
5. Mean changes from baseline in total Lequesne algofunctional index
6. Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) response criteria
7. Analysis of predictors of response
All secondary outcomes were measured at 4, 12 and 24 weeks.
Overall trial start date
Overall trial end date
Reason abandoned (if study stopped)
Participant inclusion criteria
1. Diagnosis of knee osteoarthritis (OA) according to the American College of Rheumatology criteria
2. Kellgren-Lawrence radiographic grade II or III of the knee
3. Visual analogue scale (VAS) for knee pain of at least 40mm (maximum 100mm)
4. Both genders, aged 40 years or older
5. Failure to control OA symptoms with previous or current analgesics and/ or non steroidal antiinflammatory drugs
Target number of participants
Participant exclusion criteria
1. Other rheumatic or inflammatory condition
2. Symptomatic disease of the lower limbs (other than knee OA)
3. Serious and/or uncontrolled concomitant medical illness
4. Body mass index (BMI) greater or equal to 35kg/m2
5. IA injection of corticosteroid or hyaluronic acid in the previous 6 months
6. knee replacement in the targeted joint
7. Local or systemic infection
9. Skin lesions in the IA injection site
10. Physical therapy for the knee
11. Known hypersensitivity to corticosteroids or lidocaine; and the use of anticoagulants
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
Rua Maria Bucalem Haddad
Investigator initiated and funded (Brazil)
Funding Body Type
Funding Body Subtype
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Basic results (scientific)
2015 results in: http://www.ncbi.nlm.nih.gov/pubmed/26136485